NCT02309515View on ClinicalTrials.gov

Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 11, 2015

Primary Completion Date

April 28, 2017

Study Completion Date

July 21, 2017

Conditions
Monoclonal B-Cell LymphocytosisStage 0 Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage I Small Lymphocytic Lymphoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Pneumococcal 13-valent Conjugate Vaccine

Given IM

Trial Locations (3)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER